These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22264247)

  • 21. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
    Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety and efficacy of enfuvirtide therapy for HIV infection in patients with hemophilia: a case series.
    Polizzotto MN; Street AM; Wright E
    Clin Infect Dis; 2007 Aug; 45(4):e39-41. PubMed ID: 17638184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.
    Ball RA; Kinchelow T;
    J Am Acad Dermatol; 2003 Nov; 49(5):826-31. PubMed ID: 14576660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enfuvirtide for nurses: answering patient questions on activity, safety, and lifestyle impact.
    Glutzer E; Lalezari JP
    J Assoc Nurses AIDS Care; 2005; 16(5):26-34. PubMed ID: 16433107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enfuvirtide injection site reactions: a clinical and histopathological appraisal.
    Wallace BJ; Tan KB; Pett SL; Cooper DA; Kossard S; Whitfeld MJ
    Australas J Dermatol; 2011 Feb; 52(1):19-26. PubMed ID: 21332688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enfurvirtide safety in human immunodeficiency virus-infected children.
    Baylor MS; Johann-Liang R
    Pediatr Infect Dis J; 2005 Apr; 24(4):389-90. PubMed ID: 15818309
    [No Abstract]   [Full Text] [Related]  

  • 27. Enfuvirtide and cutaneous injection-site reactions.
    Mirza RA; Turiansky GW
    J Drugs Dermatol; 2012 Oct; 11(10):e35-8. PubMed ID: 23134996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced HIV-infected patients: understanding physician and patient perspectives.
    Horne R; Cooper V; Fisher M
    AIDS Care; 2008 Oct; 20(9):1029-38. PubMed ID: 18825512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Fusion inhibitor enfuvirtidE. Continuous virologic and immunologic response].
    Schäfer B
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():31. PubMed ID: 16385869
    [No Abstract]   [Full Text] [Related]  

  • 30. Successful desensitization of enfuvirtide after a first attempt failure.
    Machado ES; Passoni LF; Sidi LC; Andrade HB; De Menezes JA
    AIDS; 2006 Oct; 20(16):2130-1. PubMed ID: 17053365
    [No Abstract]   [Full Text] [Related]  

  • 31. [Enfuvirtide in HIV patients: a nursing guideline for medication management].
    Bigler S; Nicca D; Spirig R;
    Pflege; 2009 Feb; 22(1):29-38. PubMed ID: 19173176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA notifications. Enfuvirtide has new instructions.
    AIDS Alert; 2007 Apr; 22(4):44-5. PubMed ID: 17595723
    [No Abstract]   [Full Text] [Related]  

  • 33. Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials.
    Palladino C; Briz V; González-Tomé MI; León Leal JA; Navarro ML; de José MI; Ramos JT; Muñoz-Fernández MA
    AIDS Res Hum Retroviruses; 2010 Mar; 26(3):301-5. PubMed ID: 20334565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 35. Acute hypersensitivity reaction to enfuvurtide upon re-challenge.
    Beilke MA
    Scand J Infect Dis; 2004; 36(10):778. PubMed ID: 15513412
    [No Abstract]   [Full Text] [Related]  

  • 36. [Spanish recommendations for proper use of enfuvirtide].
    Ribera E; Moreno S; Viciana P; Echevarría S; Flores J; Francés A; Gómez-Sirvent JL; González J; Hernández-Quero J; Lozano F; Mallolas J; Muñoz A; Ocampo A; Portilla J; Pulido F; Rivero A; Santos J; Soriano V; Antela A; Arazo P; Arribas JR; Cervantes M; Domingo P
    Enferm Infecc Microbiol Clin; 2007 Feb; 25(2):131-42. PubMed ID: 17288910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fuzeon: avoiding injection-site reactions.
    AIDS Treat News; 2006; (421):5. PubMed ID: 17405216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short communication safety, tolerability and pharmacokinetics of enfuvirtide administered by a needle-free injection system compared with subcutaneous injection.
    Gottlieb M; Thommes JA;
    Antivir Ther; 2008; 13(5):723-7. PubMed ID: 18771056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enfuvirtide doubles chances for suppression.
    AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
    [No Abstract]   [Full Text] [Related]  

  • 40. A delayed hypersensitivity reaction to enfuvirtide after rechallenge.
    Emerson CR; Post JJ; Workman C
    Int J STD AIDS; 2009 Apr; 20(4):288-9. PubMed ID: 19304981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.